Senores Pharmaceuticals Limited (NSE:SENORES)

India · Delayed Price · Currency is INR

1,513.30

-37.60 (-2.42%)

Aug 20, 2026, 3:29 PM IST

Senores Pharmaceuticals Financials Overview

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	6,803	6,326	3,983	2,145	353.37	141.7
Revenue Growth	51.49%	58.85%	85.65%	507.07%	149.38%	-
Gross Profit	4,243	3,810	2,108	1,057	225.41	60.95
Operating Income	1,581	1,371	728.8	315.8	108.94	12.47
Net Income	1,274	1,164	585.6	314.5	84.33	9.91
Earnings Per Share	28.30	26.39	16.10	12.21	6.65	1.81
EPS Growth	63.92%	63.89%	31.88%	83.61%	267.92%	-

Revenue by Geography

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
India	1,049	474.3	55.09	58.33
outside India	2,933	1,671	298.28	83.37
Total	3,983	2,145	353.37	141.7

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Investments	1,596	1,596	3,855	128.6	1	32.15
Total Debt	3,420	3,420	3,148	2,576	625.94	147.55
Net Cash (Debt)	-1,824	-1,824	707.5	-2,448	-624.94	-115.4
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-40.53	-41.37	19.45	-94.99	-49.27	-21.05

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Cash Flow	-	620.5	-459.2	-257	-10.79	-104.47
Capital Expenditures	-	-2,647	-1,575	-518.3	-472.77	-106.82
Free Cash Flow	-	-2,027	-2,034	-775.3	-483.56	-211.29
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Gross Margin	62.37%	60.22%	52.94%	49.25%	63.79%	43.01%
Operating Margin	23.25%	21.67%	18.30%	14.72%	30.83%	8.80%
Pretax Margin	25.44%	25.31%	17.72%	11.63%	35.20%	8.07%
Profit Margin	18.72%	18.40%	14.70%	14.66%	23.86%	6.99%
FCF Margin	-	-32.04%	-51.08%	-36.14%	-136.84%	-149.11%

Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug '26 Aug 20, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
PE Ratio	53.48	30.06	44.87	-	-	-
Forward PE	39.63	25.94	-	-	-	-
PS Ratio	10.24	5.53	6.60	-	-	-